Home Page Overall Ranking ROE Ranking P/E Ranking Dividend Yield Capitalization Our eBook Our Book Contact










Isin US62855J1043
Ticker MYGN
Company MYRIAD GENETICS
Currency $
Price
Aware Investor Index (AII) 0.2159
Recommendation HOLD
P/E 18.11
ROE 11.63 %
Capitalization 2,031,840,000 $
Dividend Yield 0.00 %
P/S 2.63
AII Position 412
P/E Position 236
ROE Position 313
Capitalization Position 643
Dividend Yield Position 596
Sales 772,600,000 $
10-Year Average Earnings 112,174,300 $
Shares Outstanding 72,000,000
Equity 964,900,000 $
Dividend per Share 0 $
Industry Biotechnology
Country United States
MYRIAD GENETICS Investor Relations Web Site http://investor.myriad.com







Sales:

YEAR MONTH AMOUNT
2018 6 772,600,000.00 $
2017 6 769,900,000.00 $
2016 6 740,500,000.00 $
2015 6 722,500,000.00 $
2014 6 778,216,000.00 $
2013 6 613,165,000.00 $

Earnings:

YEAR MONTH AMOUNT
2018 6 131,100,000.00 $
2017 6 20,500,000.00 $
2016 6 117,200,000.00 $
2015 6 79,800,000.00 $
2014 6 176,225,000.00 $
2013 6 147,139,000.00 $
2012 6 112,151,000.00 $
2011 6 100,710,000.00 $
2010 6 152,303,000.00 $
2009 6 84,615,000.00 $

Equity:

YEAR MONTH AMOUNT
2018 6 964,900,000.00 $
2017 6 768,000,000.00 $
2016 6 739,600,000.00 $
2015 6 661,700,000.00 $
2014 6 718,998,000.00 $
2013 6 728,594,000.00 $
2012 6 635,660,000.00 $

Shares Outstanding:

YEAR MONTH AMOUNT
2018 6 72,000,000
2017 6 68,800,000
2016 6 72,400,000
2015 6 74,500,000
2014 6 78,182,000
2013 6 83,327,000
2012 6 86,465,000

 












Bloomberg News for MYRIAD GENETICS:



Google News for MYRIAD GENETICS:

Fairfield Current - 51 minutes ago
Head-To-Head Survey: Arca Biopharma (ABIO) & Myriad Genetics ...
Myriad Genetics (NASDAQ:MYGN) and Arca Biopharma (NASDAQ:ABIO) are both medical companies, but which is the superior investment?
Seeking Alpha
Myriad Genetics down 11% on bearish reports
Myriad Genetics (MYGN -11.4%) is under pressure on almost 60% higher volume on the heels of two bearish reports from the Southern ...
News Leading (press release)
Has Myriad Genetics (MYGN) Outpaced Other Medical Stocks This ...
Myriad Genetics is a member of our Medical group, which includes 842 different ... MYGN is currently sporting a Zacks Rank of #2 (Buy).
Voice Of Analysts
Myriad Genetics (MYGN) Stock Rating Lowered by Zacks Investment ...
Myriad Genetics (NASDAQ:MYGN) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to ...
Seeking Alpha - 7 Jan 2019
Myriad Genetics Inc (MYGN) Elder Force Indicator in The Spotlight
Shares of Myriad Genetics Inc (MYGN) are being monitored closely as they have moved below the Elder Force zero line. Elder's Force Index (or ...
Zacks.com
Myriad Genetics (MYGN) Announces Positive NICE ...
Myriad Genetics, Inc. (NASDAQ: MYGN) today announced that the United Kingdom's (UK) National Institute for Health and Care Excellence ...
StreetInsider.com
Are You Looking For Opportunity on Stock? Myriad Genetics (MYGN)
Myriad Genetics (MYGN) Stock's Ratio Analysis: The Company was able to keep Return on assets (ROA) at 3.80% in the trailing twelve month.
NMSU Nеws
Delving Into The Numbers For Myriad Genetics Inc (MYGN)
The recent price of 28.22 for shares of Myriad Genetics Inc (MYGN) has put the price level below the Balance Step, indicating a near-term ...
Zacks.com - 6 days ago
Guide to Analyst Recommendations: Myriad Genetics (MYGN)
Myriad Genetics (MYGN) moved 1.45% to 29.34 on Tuesday. Myriad Genetics received interesting focus from Active Investors and it has been trading on front ...
Fairfield Current
Myriad Genetics (MYGN) to gain $39.67 in short term period
Myriad Genetics (MYGN) stock managed performance -3.38% over the last week and switched with performance of -1.72% throughout past one month period.


Back